Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The rising prevalence of Chronic Kidney Disease (CKD) among aging populations poses a significant public health challenge. This study aimed to evaluate the effectiveness of a mobile health (mHealth) intervention on the one-year incidence of CKD and the rate of eGFR decline among older adults in Vietnam.
In this randomized controlled trial, 702 community-dwelling adults aged ≥60 years with an eGFR ≥60 mL/min/1.73m² were recruited and randomly assigned (1:1) to an intervention (n=351) or a control group (n=351). The intervention group received a 12-month mHealth program featuring weekly educational messages and monthly coaching calls. The control group received standard educational pamphlets. The primary outcome was incident CKD (eGFR <60 mL/min/1.73m², confirmed after ≥90 days). A key secondary outcome was the mean annual change in eGFR. Outcome assessors were blinded to group allocation. Analyses were performed on an intention-to-treat basis.
Baseline characteristics were well-balanced; mean age was 67.4 (SD 5.2) years. The incidence of new-onset CKD was 8.5% (30/351) in the intervention group versus 11.1% (39/351) in the control group. The mHealth intervention reduced the risk of new-onset CKD (HR = 0.76, 95% CI: 0.59-0.97, p = 0.03). Furthermore, the intervention group experienced a significantly slower mean annual decline in eGFR compared to the control group (-1.2 vs. -2.1 mL/min/1.73m²; mean difference, 0.9; p = 0.04). A pre-specified interaction analysis showed the intervention's benefit on the primary outcome was concentrated among participants without type 2 diabetes (T2D) (p-interaction = 0.02), while a significant effect was not demonstrated among those with T2D (HR = 0.94, 95% CI: 0.67-1.32).
A 12-month mHealth intervention resulted in a lower incidence of new-onset CKD and a slower rate of eGFR decline among older adults. While the benefit for CKD incidence was not demonstrated in the subgroup with T2D, possibly due to limited statistical power, mHealth remains a promising preventative strategy. More intensive interventions may be required for high-risk diabetic populations.
